Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Subscribe To Our Newsletter & Stay Updated